- Stocks
- Healthcare
- NASDAQ: ICPT

Price (delayed)

$18.20

Market cap

$603.4M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.73

Enterprise value

$1.07B

Sector: Healthcare

Industry: Biotechnology

The EPS has grown by 37% year-on-year and by 19% since the previous quarter

The net income has grown by 36% year-on-year and by 19% since the previous quarter

The quick ratio has declined by 21% year-on-year but it is up by 9% since the previous quarter

The equity has contracted by 20% from the previous quarter

ICPT's debt is up by 5% year-on-year

What are the main financial stats of ICPT

Market
Valuations
Earnings

Shares outstanding

33.15M

Market cap

$603.4M

Enterprise value

$1.07B

Price to earnings (P/E)

N/A

Price to book (P/B)

N/A

Price to sales (P/S)

1.87

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

3.33

Revenue

$321.7M

EBIT

-$173.62M

EBITDA

-$164.33M

Free cash flow

-$129.78M

Per share
Balance sheet
Liquidity

EPS

-$6.73

Free cash flow per share

-$3.92

Book value per share

-$6.06

Revenue per share

$9.71

TBVPS

$15.69

Total assets

$520.11M

Total liabilities

$720.11M

Debt

$568.11M

Equity

-$200M

Working capital

$341.33M

Debt to equity

-2.84

Current ratio

3.33

Quick ratio

3.15

Net debt/EBITDA

-2.85

Margins
Efficiency
Dividend

EBITDA margin

-51.1%

Gross margin

98.4%

Net margin

-69.1%

Operating margin

-55.1%

Return on assets

-38.2%

Return on equity

N/A

Return on invested capital

-19.1%

Return on capital employed

-46.4%

Return on sales

-54%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Intercept Pharmaceuticals stock price performed over time

Intraday

7.37%

1 week

-5.01%

1 month

-17.91%

1 year

-79.88%

YTD

-26.32%

QTD

-21.14%

How have Intercept Pharmaceuticals's revenue and profit performed over time

Revenue

$321.7M

Gross profit

$316.42M

Operating income

-$177.14M

Net income

-$222.32M

Gross margin

98.4%

Net margin

-69.1%

Intercept Pharmaceuticals's operating margin has surged by 52% YoY and by 26% QoQ

ICPT's net margin is up by 46% year-on-year and by 21% since the previous quarter

Intercept Pharmaceuticals's operating income has increased by 43% YoY and by 23% QoQ

The net income has grown by 36% year-on-year and by 19% since the previous quarter

What is Intercept Pharmaceuticals's growth rate over time

What is Intercept Pharmaceuticals stock price valuation

P/E

N/A

P/B

N/A

P/S

1.87

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

3.33

The EPS has grown by 37% year-on-year and by 19% since the previous quarter

The equity has contracted by 20% from the previous quarter

ICPT's price to sales (P/S) is 97% lower than its 5-year quarterly average of 62.1 and 51% lower than its last 4 quarters average of 3.8

ICPT's revenue is up by 18% year-on-year and by 2.9% since the previous quarter

How efficient is Intercept Pharmaceuticals business performance

The ROS has soared by 51% year-on-year and by 26% since the previous quarter

Intercept Pharmaceuticals's return on invested capital has increased by 31% YoY and by 20% QoQ

Intercept Pharmaceuticals's return on assets has increased by 15% YoY and by 14% QoQ

What is ICPT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ICPT.

How did Intercept Pharmaceuticals financials performed over time

The total assets is 28% smaller than the total liabilities

Intercept Pharmaceuticals's current ratio has decreased by 21% YoY but it has increased by 9% from the previous quarter

The quick ratio has declined by 21% year-on-year but it is up by 9% since the previous quarter

Intercept Pharmaceuticals's debt to equity has surged by 82% YoY and by 15% QoQ

The equity has contracted by 20% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.